X
Search
X

Patient Support Hotline

Call (844) 244-1309

ZERO360 is a free, comprehensive patient support service to help patients and their families navigate insurance and financial obstacles to cover treatment and other critical needs associated with cancer.

X

Subscribe to our E-Newsletter

Stay up-to-date on the latest news about prostate cancer. Join our distribution list to receive periodic email updates and our monthly e-newsletter.

  • Patient Support (844) 244-1309
  • Search
  • e-News Signup Enews Signup
  • Run/Walk
  • Donate

$200K Saved With First-Line Docetaxel for Prostate Cancer

Two systemic drugs for the treatment of newly diagnosed metastatic prostate cancer, docetaxel (Taxotere, Pfizer) and abiraterone acetate (Zytiga, Janssen), which have comparable overall survival benefits, have hugely different costs, according to a new cost-effectiveness modeling analysis. In the modeling study, adding docetaxel to ADT increased cost by $12,185, whereas adding abiraterone to ADT increased cost by $208,684.

Read more. 

source: Medscape